Alexion receives FDA authorization for Soliris to treat atypical Hemolytic Uremic Syndrome The U.

The accelerated acceptance program allows the company to approve a drug to treat a serious disease predicated on clinical data displaying that the medication has an effect on an endpoint that is reasonably more likely to predict a clinical advantage to sufferers, or on an effect on a clinical endpoint other than survival or irreversible morbidity. Soliris is usually marketed by Alexion Pharmaceuticals in Cheshire, Conn.. Alexion receives FDA authorization for Soliris to treat atypical Hemolytic Uremic Syndrome The U.S.Markets by Marcelo Olivares, G-rard P. Cachon.

A genetic tool for cleaner water A genetic tool used by medical researchers could also be used in a novel method of remove harmful microbes and viruses from normal water. In a series of proof-of-concept experiments, Duke University engineers demonstrated that brief strands of genetic material could successfully target a matching part of a gene in a common fungus found in drinking water and make it go wrong. If this new strategy could be perfected, the experts believe that it could serve as the foundation for a device to help solve the issue of safe drinking water in Third World countries without water treatment facilities.